Skip to main content
CELC $56.31 +1.28%
CELC logo
CELC · Celcuity Inc.
Track CELC — free
$56.31 +0.71 (+1.28%) At close · Nov 19 Play latest call Q3 2026 earnings call transcript
Market Cap
$2.77B
Shares
49.13M
Volume · Nov 19 1.46M Avg daily vol (3M) 1.25M
All webcasts

Conference · 2026-09-09

Celcuity Inc. (CELC) September 9, 2026 Conference Transcript

Concluded Sep 9, 2026 Audio replay
Sep 9, 2026 28:25 48 turns
Period
2026-09-09
Runtime
28:25
Sources
2 artifacts

Transcript & audio

28:25 Audio
Joseph Eric Analyst — Citi

Thank you, everyone, and welcome to Citi's Back to School Biopharma Summit. I'm Eric Joseph, Senior Biotech Analyst with the firm, and one of our first fireside sessions this morning is with Cellcuity, and it's my pleasure to be joined by company CEO Brian Sullivan to discuss the company. So, Brian, thanks for joining us.

You're welcome. Thanks for having me.

Joseph Eric Analyst — Citi

Maybe for anyone less familiar with the company, Brian, we could perhaps have you start out by just providing some high-level remarks, and then we'll hop in a Q&A.

Sure. So our lead candidate is actually now an approved drug, RevTripic, which is a pan-PI3K mTORC1-2 inhibitor, and we recently received approval for a second-line indication in HR-positive, HER2-negative advanced breast cancer. We are getting ready to launch this quarter. We also have two Phase III studies in the first-line setting in HR-positive breast cancer, one for patients who are endocrine-sensitive, then another one for patients who are endocrine-resistant. And we have an additional study ongoing in prostate cancer that is in the early stage, phase 1B2, and we expect to provide updated results towards the end of this year on that study.

Joseph Eric Analyst — Citi

Okay, great. Well, let's pick up on the proctorpic launch. You know, we're kind of in this interim period before products ship and start to go out. But can you just frame where things are with respect to just from a product awareness standpoint among oncology providers and, you know, and just sort of the groundwork that's been put in place to support access?

Sure. So we began preparing for this launch two and a half years ago, and that included primarily initially at least building out the organization, ensuring that we had the appropriate team. We finished building that organization except for the Salesforce last year and then added the Salesforce members. We have 90 folks, oncology sales specialists, in the second quarter. And so they began profiling accounts, working with doctors prior to having approval. They couldn't educate doctors on the data, but they could get an understanding of the physician's tendencies towards what they used to treat patients. They could lay groundwork for the accounts in other ways. Our market access teams have been working with national accounts, which are the payers, for the past 18 months. Because they have safe harbor, we could present data. We could familiarize them with the product. And then similarly, with strategic accounts, you know, these are the Dana-Farber's U.S. Oncologies of the World. You can work with them because they create a lot of what are considered to be clinical pathways. They essentially define the treatment paradigm for not only their institutions, but they also offer these pathways to other institutions. So with these strategic accounts, they have outweighed a very significant influence beyond just the group of patients they may be treating at their facilities. And so now we have our sales force has been meeting with doctors with the data. We've had two phase three data releases. We released our wild type data July 24, 25 rather, and then we released our mutant data. This is PIC3C mutant data at ASCO. And so with those two data releases, because the data was, we believe, was unprecedented in terms of the level of results that we were able to report, it got a lot of attention. And so prior to the launch, we conducted an unbranded campaign to educate doctors, physicians, about the importance of the PAM pathway, P3K-AKTM pathway, as well as the importance of comprehensively inhibiting it. So we can't promote the drug, we can't mention our drug, but we can educate them about the pathway and the relevance, in particular, of our mechanism of action. And so now that we have approval, we have our Salesforce meeting with doctors. We have each of these oncology sales specialists as a business plan. They have a target number of doctors within their territory. They understand the priority of doctors and accounts to work with, and that's been going very well. And then you overlay that with other programs, whether it can include digital marketing or other ways of getting in front of doctors. And we assess that. And so we think we have created significant awareness to date amongst not just the academics or the KOLs who I think have been following us because that's part of what they do, but also more importantly amongst the community docs who represent or rather treat approximately 80% of breast cancer patients.

Joseph Eric Analyst — Citi

Okay, great. I know that having clarity on a second manufacturing site is a key step that you want to have in place before beginning shipments later this quarter. What's the approval status of that second site today, and how should we be thinking about the scale of market reach, right? How much of the market you can serve once you start shipping commercial product? Sure.

So the second site is really there to provide additional capacity. Our first site can provide the capacity we need for the initial launch. We want visibility in the review process of the FDA. We submitted a post-approval supplement that contained the validation data for the batches that this manufacturer ran. You know, the process is very robust. We've gone through a review just a few months ago for our CMC package and processes and specifications and analytical methods. So very confident about that. And now it's just a matter of having initial interaction with the FDA to understand or to gain confidence that somehow something new isn't going to pop up. So we don't need them to be approved. We don't need that PAS to be approved. We just want line of sight that it'll follow a normal course.

Joseph Eric Analyst — Citi

Can you say more about how that light of sight has provided, I guess, the interaction?

The interaction with the FDA. And once you submit, you'll typically get information requests. And those interactions essentially provide a perspective that we'll assess. I mean, we've been interacting with the agency for five years on this particular drug and a lot of familiarity with the individuals involved. And so, again, we just are somewhat being cautious. We're confident about the data. We just don't want to be blindsided.

Joseph Eric Analyst — Citi

Okay, got it. And I know that an expanded access program is already open. Can you discuss the pull through that you're seeing into that program currently and sort of how patient eligibility is determined?

Sure. So we just put that in place a couple weeks ago, and it's targeting or it's limited to patients who would be otherwise indicated for the drug, essentially the patients who would be consistent with the label population. And one of the challenges of any EAP, which is essentially considered a clinical trial, it's an expanded access protocol. And because it falls into that category of approach, each site needs to approve that protocol. And for larger sites that may have their own IRBs, institutional review boards, that process can be quite extended. And because the window of time that, you know, we won't be having product available, it's very difficult for some of these larger sites to actually take advantage of it. Whereas the community sites or smaller sites that essentially are willing to rely on a central IRB approval, which we have, the process is much easier. So we've gotten a lot of interest. Patients are on the drug through this. And more importantly, I think it's signaled to the community that we want to do everything we can to make sure product is available for their patients. And we'll work with them if it's possible for their institution to take advantage of the program.

Joseph Eric Analyst — Citi

Okay. Okay. But I guess from a, you know, for all the folks who are tracking estimates and so forth like that, from a reporting standpoint, I'm just curious whether EAP demand or any volumes get reflected as sales and whether you'd expect that to be a meaningful...

So, no, they won't get reflected as sales. We're offering this drug. It's considered a clinical trial. We're providing this drug. In the context of that clinical trial, it's, in effect, free of charge. Okay. And once the drug is commercially available, those patients will be transitioned to commercially available product. Okay.

Joseph Eric Analyst — Citi

Great. Great, great, great. So I guess in the wild type PI3 kinase setting where Riftorpec is approved today, you know, you're talking about a market here that's roughly the same size as HR positive HER2 negative breast cancer with PI3 kinase alpha. If you are excluding patients with ESR1 mutation, if I have that kind of rough math correct, from a benchmarking standpoint, is it useful to look at sort of the launch trajectories of other PI3K alpha products here? Here I'm thinking of TruCap, for example. Can we think about sort of, you know, in demand as a comp here for RepTorpec?

So I think there are two profiles of companies that end up launching drugs these days. You know, one is the major pharmaceutical companies or ones that are already in the market and maybe already in the indication that they're launching a new drug. And those companies will have an advantage and will be able to reach peak sales probably within 24 months. I think that would be the typical result, and we've tracked that. Whereas companies like ours, launching their first drug into a new space, the time to peak, based on the analogs that we've found, is closer to 36 to 42 months. And 36 months is probably more realistic. And so I think when you think of it that way, and you reflect on the importance of the time to peak on the actual early sales, then the analogs of, let's say, a true cap aren't quite applicable. Okay. Okay.

Joseph Eric Analyst — Citi

That's helpful. And just, you know, you're approved with two regimens here, a doublet with full restaurant and then a triplet with full restaurant and public site. What's your sense of which combo regimen, you know, docs are more likely to treat with here? And do you anticipate any, you know, payer pushback, payer limitations with respect to the use of a triplet regimen, you know, in any sense? You know, perhaps putting Getta and, you know, Publocyclob in a little bit of tension.

Sure. So two things. One is that by having two regimens, we've actually, I think, increased our ability to optimize the penetration of usage of Getta because there's a very heterogeneous population in breast cancer. You know, 30-year-old woman, in some cases, up to 75- or 80-year-old woman. And so giving doctors two options that they can use to essentially optimize for their patient, depending on their characteristics, will be very helpful. And that's the feedback we've received. However, for the triplet, the research that we've done to date has shown, suggested at least, that we would expect roughly an 80-20 split between the triplet and the doublet. And part of that may be informed by the fact that some doctors have indicated they'll start with a triplet. They always have the option, if they're concerned about the neutropenia from palbociclib, to back off the palbociclib. Alternatively, we've had some doctors tell us that, well, they'll start with the doublet and then allow the patient to see how the patient's doing and then potentially add palbociclib once that patient has received a cycle of therapy or so. And so I think that flexibility will be very helpful to the doctors because, again, they can select what they think might be best depending on the patient's profile. And that's always a challenge with any regimen, especially in breast cancer where you have such a wide range of patient subtypes.

Joseph Eric Analyst — Citi

From your discussions with docs, do you anticipate use of Reptorpic in patients with an ESR, with ESR1 mutation? I guess, yeah, and I guess, you know, if they were to do that, would they use the doublet, right, combination as per label, or would they kind of seek to perhaps do a novel combination with an oral CERD?

So I think it'd be helpful just to step back and think about these segments. There's roughly 40% of patients that lack a PIC3CA mutation or an ESR1 mutation. They're double wild type. There's about 40% of patients that have a PIC3CA mutation, and they may have or have not an ESR1 mutation. And then there's 20% of patients that are PIC3CA wild-type that have an ESR1 mutation. So I think in the two groups of patients, PIC3CA wild-type, ESR1 wild-type, and the PIC3CA mutant, the getter regimens will be very, very competitive. They're highly differentiated in efficacy and safety profile, and we think that will be a significant, comprise a significant proportion of the regimens that doctors are prescribing. In that subgroup, that 20% portion that are PIC3CA wild type ESR1 mutant, it'll be more competitive. I think there's a very strong rationale to use the getter regimens when you look, especially when you dig into some of the subgroups that we've reported on in terms of the duration of response, patients with or without visceral mets, characteristics like that allow you to see some fairly significant differentiation from the regimens that include an oral CERD.

Joseph Eric Analyst — Citi

Okay. Okay. When we look at the results from study one, Victoria one, you know, there's a little bit of discord in the PFS duration on the triplet regimen versus the doublet. And I'm wondering whether, and I know there are some regional differences in that discord, I'm wondering whether there are any Any implications from that signal as we think about the real-world duration on therapy with Rev. Torbic here in the U.S.?

Sure. I actually think the population that we enrolled was a tougher population than the population you would see in the real world. In our eligibility criteria, we require patients that have measurable disease. And in the real world, you'd find roughly 20% to 30% of patients with non-measurable disease, bone-only disease. And interestingly, when we look at the subgroups and look at patients who, for instance, don't have visceral disease or don't have measurable disease, the median PFS, the duration on therapy, is significantly longer than those with measurable disease. And that's consistent across the mutant and wild-type subgroups. And so we actually think there's limited downside to the duration of treatment that we reported for the Victoria One study, roughly 10 months duration of treatment average. And in fact, if anything, there could be upside, given the nature of the population that exists in the real world. Okay.

Joseph Eric Analyst — Citi

Okay, great. So let's turn to the PI3K mutant opportunity here. You're expecting to file an S&DA this quarter. No, we actually already filed. Oh, excuse me.

Sorry.

Joseph Eric Analyst — Citi

My bad. I guess from a review standpoint, are you similarly expecting a priority review timeline for that?

We haven't heard from the FDA on that. We're assuming sometime in the second quarter, and we'll see once they do their review, and we presume, hopefully, accept our submission. And that's two months from the time of submission.

Joseph Eric Analyst — Citi

And I guess, you know, assuming approval, can you talk about sort of the operational work that kind of is still to be done, perhaps in support of an expanded launch and whether there's any added scale up to, you know, product capacity, manufacturing capacity to serve the wider eligible market?

Sure. So we have a production forecast that's linked to our sales forecast. One of the reasons why we're focused on having our second manufacturer is to ensure that we have sufficient capacity, because we expect to get significant penetration in this market, and then with the addition of an indication we expect in patients with these mutations, we would expect even greater volume. So we're also working to validate two other manufacturers. So we hope to exit 27 with four validated manufacturers for Reptropic.

Joseph Eric Analyst — Citi

Okay. I kind of think there's going to be some interest from physicians who would seek to treat patients with mutant PI3 kinase alpha breast cancer, you know, as soon as the product becomes available. You know, are payers, maybe you can sort of speak to that interest and then whether payers are likely to support access and reimbursement in the mutant PI3K population ahead of an expanded approval and, you know, what role, you know, guidelines might play here.

So we can't promote an off-label indication, but what can happen is that NCCN, if there's published data available, can make the decision to add, in this case, a recommendation for, let's say, in this case, the PIC3CA mutation population. If that were to occur, that would provide the level of, in fact, evidence for payers to potentially make a reimbursement decision. But again, it's not something that we can really promote at all. And our focus is on getting the drug approved or getting the drug approved after pick approved for that patient population. Okay.

Joseph Eric Analyst — Citi

Obviously, you're not done here with development of GETA and advanced breast cancer. You're running a frontline study, the Victoria 2 trial. Can I just sort of get you to give us a snapshot of that trial and sort of some rough guidance as to when you expect readouts from that study?

So there are roughly 90,000 women a year who are diagnosed with metastatic breast cancer and have not yet received treatment for that metastatic disease. 60,000 of them have what's considered to be endocrine-sensitive disease. And these are women who had early breast cancer and were seemingly out of the woods and unfortunately recurred a number of years later. And they'll typically get roughly 25 months of benefit from currently available therapy. We ran a phase 1b study in that population and reported median PFS of 48 months, very, very extended timeline, time for these patients. And so that gives us optimism about the ability of Geta, when combined with pavociclib and letrozole, to potentially improve the standard of care for that patient population. The second group of patients, roughly 30,000 or so, are considered to be endocrine-resistant, and these are women who didn't get much benefit from their adjuvant tamoxifen or letrozole that they received after they were treated for their early breast cancer, and so they have a much tougher prognosis. They're only getting seven to eight months of benefit from the current standard of care therapies, and so it's a very significant unmet need for these women. That study is essentially separately powered, separately conducted within the overall protocol of Victoria 2, and will have independent timelines. We would expect data from that population to be available earlier than the endocrine-sensitive population, just because of the shorter duration of benefit expected in the control arm in this case.

Joseph Eric Analyst — Citi

I appreciate that you'd expect a readout from the endocrine-resistant population a little bit earlier, but I guess from the expected PFS duration, I guess, from the control arm, we're thinking perhaps a readout in what time frame, do you think?

Late 28, 29. Okay.

Joseph Eric Analyst — Citi

Got it. Okay. Maybe we could move to prostate cancer, right? Which is where you're running a phase one B study right now. And you'll present some data there, I think, in the fourth quarter this year. I guess from a readout standpoint or a venue standpoint, I guess, how are you thinking about where those data might be presented? Are you targeting a medical meeting?

A medical conference, and we'll be at ESMO. And essentially, we'll be providing an update with some additional analysis of response by various subgroups, as well as some information from patients who received a higher dose than the first two doses, first two groups of patients that we evaluated. Okay. Okay.

Joseph Eric Analyst — Citi

You know, relative to, compared with breast cancer, right, I guess, you know, you see an overrepresentation of P10 loss among, you know, various potential PAM alterations that you might see. You see P10 loss overrepresented in prostate cancer versus breast cancer. I guess, can you talk about sort of your confidence or what the preclinical data support in terms of Gettelism being, you know, responsive or P10, cancer cells with P10 loss being similarly sensitive to Gettelism, you know, versus breast cancer?

So it's interesting. Both breast cancer and prostate cancer have mutations of this pathway. PIK3CA is the primary one, and breast cancer P10 loss, as you said, is the primary one in prostate cancer. And we've done a lot of non-clinical work to characterize the activity of revtripic, getotelicib, in breast cancer cells as well as prostate tumor cells. And we have not found significant differentiation in the level of activity in terms of potency and half-maximal effect on limiting proliferation, as well as the cytotoxicity of the drug based on their mutational status. You know, P10 loss is roughly about 25% of patients, at least based on studies that have been reported out recently. And similar to the PIK3CA mutation, single-target inhibitors, such as TruCAP, for instance, which hits HKT, have really only been found to be effective in patients that have P10 loss. In effect, that's the mutation, whereas, you know, our data suggests that the P10 status won't be significantly relevant to the sensitivity or the responsiveness to refotropidic, and again, that relates back to the mechanism of action. You know, by inhibiting, you know, all four isoforms of PI3K, mTORC1,2, you are essentially shutting down that pathway, and the P10 status then becomes not so relevant.

Joseph Eric Analyst — Citi

Just coming back to the anticipated data readout at ESMO, can you just talk about sort of the, you know, the scope of the readout in terms of, I guess, volume of patients that you'll be reporting on and perhaps a sense of sort of medium follow-up?

So, I don't know offhand what the median follow-up period is. I think, you know, the most relevant aspect of the data that we'll be reporting are, you know, the different subgroups and the new dosing level that we evaluated. And then we'll also be providing an update on our next steps for evaluating gaditalisib in that patient population.

Joseph Eric Analyst — Citi

Would a sub-Q formulation be part of the discussion around next steps?

Not so much with prostate cancer. A sub-Q formulation, which we've been working on and we expect and are targeting getting approved in conjunction or around the same time, that we would expect to get approval, let's say, in the endocrine-sensitive population of breast cancer. You know, given the data that we've reported to date, given the duration of response that patients receive on standard of care, these patients could potentially be on this drug for a number of years. And so subcutaneous formulation would clearly be a benefit to those patients. It would open up the market. You know, we have much higher potential peak penetration. You know, with a subcutaneous formulation, we get that. We don't think the subcutaneous formulation in indications in the second-line setting or in the endocrine-resistant population will be necessary to achieve near-peak penetration. Certainly, when it's available, we would make it available broadly, wouldn't be independent of the patient population, but we don't think it's a key to achieving what we think is the peak potential in those settings. With prostate, again, that's at an earlier stage, and so most likely just the way the timelines will work. If our sub-Q formulation advances as we expect, it would be available in conjunction with potential. Again, a lot of things have to happen the way we want, but if those things do happen and we're successful in demonstrating in a phase three study that, again, a regimen can offer a statistically significant improvement, then the subcutaneous formulation would be available to those patients as well. Got it.

Joseph Eric Analyst — Citi

Okay. All right. Great, great.

Maybe just one last question before we wrap up. Just wondering whether sort

Joseph Eric Analyst — Citi

of what's next beyond these first, you know, broad sets of indications that you're in currently for GetAlessed, whether there's, let me take a step back, actually. What I want to get to is just really a question around business development, whether there are additional indications for GEDA that you're pursuing or looking to pursue, or whether you might seek to sort of expand the pipeline through BD.

Sure. So I would say two things. One, the development program we have in place is addressing two of the largest tumor types of all, right? Women with HR-positive breast cancer, as well as men with prostate cancer. And those indications alone, if you were to analyze the serve market potential, are tens of billions of dollars. And so we're addressing very, very important unmet needs and very, very significant populations. So that's a full plate. Now, we are also doing work, which we haven't disclosed, to expand the range of indications we could pursue, patient populations we may evaluate, or considering other drugs that could be consistent with our approach to treating solid tumors.

Joseph Eric Analyst — Citi

Okay, great. I'll hold here for any questions from the room. All right, great. Well, we'll wrap it there. Thanks very much, Brian.

Thank you, Eric. Good to see you.

Analyst Q&A · 1 question
Full-screen source Call document